In patients with acute exacerbation of COPD pH < 7.35 PCO2 > 6.5 kPa Despite 1 hour optimal treatment
Benefits Reduced mortality Reduced need for intubation More rapid improvement in RR, pH & PCO2
Decompensated OSA & OHS
Recommended as first choice OSA with acute respiratory acidosis OSA with COPD overlap Compensated hypercapnia with day time somnolence When alveolar hypoventilation fails to improve despite CPAP
Respiratory failure from neuromuscular weakness and chest wall deformities
Indicated in patients with Symptomatic chronic respiratory failure with evidence of Nocturnal or day time hypoventilation FVC < 50% predicted VC < 15-20 ml/kg MIP < -6 cm H2O MEP < 40 cm H2O
In stable NMDs patient may remain on NIV for life long e.g with spinal cord injury In progressive NMDs ,its not a cure but delays the need of invasive ventilation e.g with AML
Benefits Acceptable quality of life Avoid complications of invasive ventilation (Bleeding, tracheal stenosis, respiratory infections)
Community acquired pneumonia
Improves oxygenation in severe pneumonia Buys time for mechanical ventilation
Cystic Fibrosis
Preferred in patients with PCO2 > 55mmHg PCO2 > 50 mmHg with nocturnal desaturation
Preferred over HFNC in Patients having acute hypercapnic respiratory failure with AE COPD Associated with cardiogenic pulmonary edema Associated with OSA, OHS or NMDs
Helmet face mask is preferred to avoid risk of aerosol related spread of infection Associated with decrease intubation rate and improves mortality However further research is needed
Contraindications of BiPAP
Absolute Need for emergent intubation Severe ARDS Cardiac or respiratory arrest Unstable cardiac arrhythmia